At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,360 enrolled
Drug / intervention
Hydroxychloroquine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)
In Brief
A Phase 3 clinical trial evaluating Hydroxychloroquine and Placebo oral tablet for COVID-19. Completed, enrolled 1,360 participants across 34 sites.
Detailed Summary
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsPatient-Centered Outcomes Research Institute
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartApr 2020
Primary CompletionDec 2020
Study CompletionJan 2021
TodayJul 2026
First PostedApr 6, 2020
Enrollment StartApr 22, 2020
Primary CompletionDec 10, 2020
Study CompletionJan 9, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.2 years ago
Interventions
Hydroxychloroquinedrug
oral self administered tablet
Placebo oral tabletdrug
oral self administered tablet